Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
— “开辟新天地：原发性硬化性胆管炎的专家观点” 将邀请临床、学术和患者权益领袖讨论PSC疾病管理和不断变化的观点 关于临床开发—
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.
以色列特拉维夫，2024年4月2日（环球新闻专线）——开发创新疗法的临床阶段生物技术公司Chemomab Therapeutics Ltd.（纳斯达克股票代码：CMMB）（Chemomab）今天宣布，将于2024年4月10日星期三举办关于原发性硬化性胆管炎（PSC）的现场关键意见领袖（KOL）虚拟活动美国东部时间上午 10:00要注册，请点击这里。
The event, "Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis," will feature Christopher Bowlus, MD (UC Davis Health), Ricky Safer (PSC Partners Seeking a Cure), and Massimo Pinzani, MD, PhD, (UCL Institute for Liver and Digestive Health, UPMC ISMETT), who will provide clinical and patient perspectives on PSC, a devastating rare liver disease with no FDA-approved therapies. They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
该活动，“开辟新天地：原发性硬化性胆管炎的专家观点”， 将邀请医学博士（加州大学戴维斯分校健康中心）克里斯托弗·鲍勒斯、瑞奇·萨弗（PSC合作伙伴寻求治愈方法）和医学博士马西莫·平扎尼（伦敦大学学院肝脏与消化健康研究所，UPMC ISMETT），他们将就PSC提供临床和患者观点，这是一种没有获得美国食品药品管理局批准的疗法的毁灭性罕见肝病。他们将讨论对新的PSC疗法的迫切需求以及可能促进新药批准的新进展。
Chemomab's co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024. CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.
Chemomab的联合创始人、首席执行官兼首席安全官阿迪·莫尔博士兼首席营销官马特·弗兰克尔医学博士将概述CM-101 2期PSC临床试验，该试验将在2024年年中公布主要结果。CM-101 是一种双机制同类首创的单克隆抗体，可中和 CCL24，这是一种可溶性蛋白，是 PSC 和其他纤维炎性疾病的关键炎症和纤维化通路的关键驱动因素。
A Q&A session will follow the presentations.
演讲之后将举行问答环节。
About Christopher Bowlus, MD
Chris Bowlus, MD is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. Dr. Bowlus has an active research program bridging the basic and clinical aspects of PSC and primary biliary cholangitis (PBC), with the goal of bringing more effective treatments to patients. He is a founding member of the International PSC Study Group and leads the U.S,-based Consortium for Autoimmune Liver Disease. Dr. Bowlus is also active in supporting patient advocacy, serving as Co-Chair of the Scientific and Medical Advisory Committee of PSC Partners Seeking a Cure. He received his BA degree from the University of California San Diego and his MD degree from the St. Louis University School of Medicine. Dr. Bowlus completed a Fellowship in Gastroenterology at the Yale University School of Medicine.
关于医学博士克里斯托弗·鲍勒斯
克里斯·鲍勒斯医学博士是加州大学戴维斯分校医学院莉娜·瓦伦特教授兼胃肠病学和肝病学系主任。Bowlus博士有一个活跃的研究计划，将PSC和原发性胆源性胆管炎（PBC）的基础和临床方面联系起来，目标是为患者提供更有效的治疗方法。他是国际PSC研究小组的创始成员，并领导总部位于美国的自身免疫性肝病联盟。Bowlus博士还积极支持患者权益，曾担任PSC Partners Seeking a Curey的科学和医学咨询委员会联席主席。他获得了加州大学圣地亚哥分校的学士学位和圣路易斯大学医学院的医学博士学位。鲍勒斯博士在耶鲁大学医学院完成了胃肠病学奖学金。
About Ricky Safer
Ricky Safer is a patient living with PSC and Founder and CEO of PSC Partners Seeking a Cure, a non-profit organization whose mission is to drive PSC research to identify treatments and a cure and provide education and support for those impacted by PSC. PSC Partners collaborates with researchers, clinicians, industry and regulators to accelerate PSC research and drug development. Its many initiatives include creation of a PSC Patient Registry, an international database to create a synthetic arm for later stage clinical trials, and regulatory-grade, validated Patient-Reported Outcome Measures for major PSC symptoms. Safer serves on a number of healthcare-related boards and steering committees. She is a frequent presenter at medical conferences and has co-authored numerous posters and peer-reviewed scientific studies. Safer received a BA with honors from the University of Michigan and an MA degree from Johns Hopkins University.
关于 Ricky Safer
瑞奇·萨弗尔是一名与PSC同住的患者，也是PSC Partners Seeking a Cure的创始人兼首席执行官。PSC Partners Seeking a Cure是一家非营利组织，其使命是推动PSC研究，以确定治疗方法和治疗方法，并为受PSC影响的人提供教育和支持。PSC Partners与研究人员、临床医生、行业和监管机构合作，加速PSC的研究和药物开发。它的许多举措包括创建 PSC 患者登记处、创建用于后期临床试验的合成组的国际数据库，以及针对主要PSC症状的监管级、经过验证的患者报告结果衡量标准。Safer 在多个医疗保健相关委员会和指导委员会任职。她经常在医学会议上发表演讲，并共同撰写了许多海报和经过同行评审的科学研究。Safer 获得了密歇根大学的荣誉学士学位和约翰霍普金斯大学的硕士学位。
About Massimo Pinzani, MD, PhD, FRCP, FAASLD
Professor Massimo Pinzani is a clinical and translational hepatologist and Emeritus Professor of Medicine at University College London (UCL). Until 2023 he was Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health. Prof. Pinzani is a pioneer in researching cellular and molecular mechanisms of liver fibrosis and diagnostic and therapeutic approaches to managing liver fibrotic diseases. He has authored more than 300 peer-reviewed publications and has served as a board member of major hepatology and gastroenterology organizations, including the European Association for the Study of the Liver (EASL), and as an associate editor of major journals in the field. Prof. Pinzani was recently appointed Scientific Director of UPMC-ISMETT, a renowned center for transplantation and advanced specialized therapies in Palermo, Italy.
关于 Massimo Pinzani，医学博士，FRCP，FAASLD
马西莫·平扎尼教授是临床和转化肝病学家，伦敦大学学院（UCL）名誉医学教授。在2023年之前，他曾担任希拉·夏洛克肝病学系主任兼伦敦大学学院肝脏与消化健康研究所所长。平扎尼教授是研究肝纤维化的细胞和分子机制以及管理肝纤维化疾病的诊断和治疗方法的先驱。他撰写了300多篇经过同行评审的出版物，并曾担任包括欧洲肝脏研究协会（EASL）在内的主要肝病学和胃肠病学组织的董事会成员，并担任该领域主要期刊的副编辑。平扎尼教授最近被任命为UPMC-ISMETT的科学总监，UPMC-ISMETT是意大利巴勒莫著名的移植和高级专业疗法中心。
About CM-101
Chemomab is assessing CM-101 as a potential treatment for PSC in the Phase 2 SPRING trial. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple fibro-inflammatory disorders. Data from a Phase 2a liver fibrosis trial in nonalcoholic steatohepatitis (NASH) patients showed consistent, positive improvements in key inflammatory and fibrogenesis-related biomarkers, including several that may serve as a potential bridge to activity in PSC. Patient enrollment in the Phase 2 SPRING trial has been completed and a readout of topline data is expected midyear 2024. CM-101 has Orphan Drug status in the U.S. and E.U. and was awarded FDA Fast Track designation.
关于 CM-101
在第二阶段 SPRING 试验中，Chemomab 正在评估 CM-101 作为 PSC 的潜在治疗方法。CM-101 是同类首创的单克隆抗体，可中和 CCL24，这是一种可溶性蛋白，有助于驱动 PSC 和其他纤维炎性疾病的核心炎症和纤维化途径。在临床和临床前研究中，CM-101 似乎是安全的，有可能治疗多种纤维炎性疾病。一项针对非酒精性脂肪肝炎（NASH）患者的2a期肝纤维化试验的数据显示，与炎症和纤维化相关的关键生物标志物持续出现积极改善，其中包括几种可能作为PSC活性潜在桥梁的生物标志物。第二阶段SPRING试验的患者入组工作已经完成，预计将于2024年年中公布头条数据。CM-101 在美国和欧盟具有孤儿药地位，并获得了 FDA 快速通道称号。
A recording of the PSC KOL webinar will be available following the live session on Chemomab's website at Chemomab Investor Relations - Presentations.
PSC KOL网络研讨会的录像将在Chemomab网站Chemomab投资者关系——演示文稿的直播之后公布。
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.
Chemomab Therapeutics Ltd
Chemomab是一家临床阶段的生物技术公司，为需求未得到满足的纤维炎性疾病开发创新疗法。基于 CCL24 在促进纤维化和炎症方面的独特而关键的作用，Chemomab 开发了 CM-101，这是一种中和 CCL24 活性的单克隆抗体。在临床和临床前研究中，CM-101 似乎是安全的，有可能治疗多种严重且危及生命的纤维炎性疾病。Chemomab 报告了三项针对患者 CM-101 的临床试验的阳性结果，包括一项针对 NASH 患者的2a期肝纤维化试验和一项由研究者发起的针对严重肺损伤患者的研究。一项针对原发性硬化性胆管炎的2期试验已完成患者入组，主要数据预计将于2024年年中发布。Chemomab 用于治疗系统性硬化症的 CM-101 计划已准备就绪 2 期。有关 Chemomab 的更多信息，请访问 chemomab.com。
Contact:
联系人：
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
媒体和投资者：
芭芭拉·林德海姆
投资者与公共关系、战略传播咨询副总裁
电话：+1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
译文内容由第三方软件翻译。